Anne Wojcicki, 23andMe CEO (Jordan Vonderhaar/Bloomberg via Getty Images)
August 2, 2024 10:34 AM EDT
Deals
Diagnostics

23andMe board re­jects Anne Wo­j­ci­c­ki’s take-pri­vate plan, re­quests changes

Andrew Dunn

Senior Biopharma Correspondent

CEO Anne Wo­j­ci­c­ki’s of­fer to take her ge­net­ic test­ing com­pa­ny 23andMe pri­vate for 40 cents a share has been met with re­sis­tance from her own …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times